"My goal is to develop innovative products that can significantly improve patients’ lives and the delivery of health care. I am excited to work with entrepreneurs and scientists who share that passion."
Doug's Latest Buzz
Doug joined InterWest's healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments, and portfolio company support. He is a board member of Gynesonics, Obalon Therapeutics, PMV Pharma, QuatRx, and Sera Prognostics. Doug is also actively involved in InterWest's investments in Benvenue, Integrated Diagnostics and Invuity.
Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group.
Doug received an A.B. in economics with honors and distinction, and a B.S. in biology with distinction, from Stanford, where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton, where he graduated with honors as a Siebel Scholar and Palmer Scholar.
Since undergrad, I have focused on improving the lives of patients and how health care is delivered. With overall health care spending at such a high level, there is a tremendous need to find therapeutics and diagnostics that can improve patient outcomes while at the same time lowering overall health care costs. At InterWest, I am focused on partnering with leading entrepreneurs, physicians, and scientists to identify this next generation of health care products and successfully bring them to the market.